2,518 Shares in IQVIA Holdings Inc. $IQV Acquired by Aristeia Capital L.L.C.

Aristeia Capital L.L.C. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 2,518 shares of the medical research company’s stock, valued at approximately $444,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. American National Bank & Trust acquired a new stake in shares of IQVIA in the first quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new position in IQVIA during the first quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. increased its holdings in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. Evercore ISI increased their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research note on Wednesday. UBS Group boosted their price objective on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Finally, Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a report on Thursday, May 22nd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $229.86.

IQVIA Stock Performance

IQV stock opened at $187.75 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $31.92 billion, a price-to-earnings ratio of 27.17, a P/E/G ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $249.43. The firm has a 50 day moving average of $179.88 and a two-hundred day moving average of $167.23.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.